Horizon Therapeutics Public Limited's Revenue in the fiscal year 2022 $ 3,629.04 millions
Horizon Therapeutics Public Limited's Revenue in the fiscal year 2021 $ 3,226.41 millions
Horizon Therapeutics Public Limited's Revenue in the fiscal year 2020 $ 2,200.43 millions
Horizon Therapeutics Public Limited's Revenue in the fiscal year 2019 $ 1,300.03 millions
Horizon Therapeutics Public Limited's Revenue in the fiscal year 2018 $ 1,207.57 millions
HZNP Revenue second quarter 2023 Y/Y Growth Comment
Horizon Therapeutics Public Limited Company reported Revenue growth of 7.71% year on year in the second quarter 2023, to $ 944.00 millions, this is lower than Horizon Therapeutics Public Limited Company's recent average Revenue rise of 97.47%.
Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 128 other companies have achieved higher Revenue growth. While Horizon Therapeutics Public Limited Company' s Revenue increase of 7.71% ranks overall at the positon no. 1637 in the second quarter 2023.
Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023
Horizon Therapeutics Public Limited's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
143.15 %
19.94 %
-54.06 %
(Jun 30 2021)
HZNP's II. Quarter Q/Q Revenue Comment
Horizon Therapeutics Public Limited Company achieved in the II. Quarter 2023 below company average Revenue rise of 13.45% quarter on quarter, to $ 944.00 millions.
Although the II. Quarter 2023 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the -1% growth in the II. Quarter a year ago
Within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue quarter on quarter growth. While Horizon Therapeutics Public Limited's Revenue growth quarter on quarter, overall rank is 908.
Horizon Therapeutics Public Limited Company achieved in the II. Quarter 2023 below company average Revenue rise of 13.45% quarter on quarter, to $ 944.00 millions.
II. Quarter 2023 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -1% in the II. Quarter a year ago.
Within Major Pharmaceutical Preparations industry 102 other companies have achieved higher Revenue quarter on quarter growth. While Horizon Therapeutics Public Limited's Revenue growth quarter on quarter, overall rank is 908.
Horizon Therapeutics Public Limited's 12 Months Revenue Growth Year on Year
Horizon Therapeutics Public Limited showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Horizon Therapeutics Public Limited's annual Revenue improvement would be -4.45% year on year to $3,643 millions.
In the Healthcare sector 138 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 370 to 493.
Horizon Therapeutics Public Limited showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Horizon Therapeutics Public Limited's annual Revenue decline would be -4.45% year on year to $3,643 millions.
In the Healthcare sector 138 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 370 to 493.
About Horizon Therapeutics Public Limited Revenue Growth Rates (HZNP), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
What’s included here
Company: Horizon Therapeutics Public Ltd Co
(CIK 1492426).
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
13.49%